-
Mashup Score: 0
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the phase III CONTACT-03 trial. 1 The results of this study were published in The Lancet to coincide with the presentation at the 2023 ASCO Annual Meeting. 2 According to central review, median progression-free
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The CONnected CUstomized Treatment Platform in patients with metastatic BC receiving palbociclib - 6 month(s) ago
Ilana Graetz, PhD, Emory University, Atlanta, GA, discusses a study aimed to pilot test a mobile health intervention, the CONnected CUstomized Treatment Platform, in women with hormone receptor-positive, metastatic breast cancer. The intervention included a smartbox for real-time adherence monitoring, text message reminders for missed or extra doses, and referrals to the oncology provider or a financial navigation program as needed. Out of 29 participants, 72.4% used the smartbox, and the adherence rate for palbociclib was 95.8% ± 7.6%. Only a few participants had adherence barriers at baseline. There were no significant changes in self-reported adherence, symptom burden, or quality of life over three months. The usability score of the CONnected CUstomized Treatment Platform was 61.9 ± 14.2. The study concluded that the intervention was feasible and resulted in high adherence, but further improvements in usability should be explored. This interview took place at the American Society of
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ASTRO 2023 Annual Meeting - 6 month(s) ago
W. Choi1, Y. Jia1, J. Kwak2, A. P. Dicker1, N. L. Simone1, E. Storozynsky3, V. Jain1, and Y. Vinogradskiy1; 1Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, 2University of Colorado School of Medicine, Aurora, CO, 3Department of Cardiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia,…
Source: astro2023.eventscribe.netCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1What is the role of CDK4/6 inhibitors in early breast cancer? - 6 month(s) ago
Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, gives an overview of current CDK4/6 inhibitors in early breast cancer. Recent trials such as the Phase II NATALEE trial (NCT03701334) of ribociclib plus endocrine therapy, the Phase II monarchE trial (NCT03155997) of abemaciclib and the Phase III Penelope-B trial (NCT01864746) of palbociclib have all demonstrated promising results. Prof. Gnant additionally talks on the PHERGain trial (NCT03161353) of dual HER2 blockade in early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Hot Topics in Renal Cell Carcinoma and Rare Tumors - 6 month(s) ago
In this podcast we’ll hear from experts in GU cancer on some of the most exciting clinical trial data in…
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumors - 6 month(s) ago
Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, compares the real-world data of belzutifan in VHL-associated tumors versus clinical trial data. The objective response rate (ORR) for associated renal cell cancer was 23%, lower than the clinical trial’s 49%, likely due to shorter follow-up duration (8 months vs. 21 months) and less frequent scans. Safety findings were similar, with common side effects being anemia and fatigue (65-70%). Belzutifan dose was decreased in 30% of our patients (vs. 15% in the clinical trial) due to poorer performance status (ECOG 1-2 vs. ECOG 0). These results highlight the importance of longer follow-up and more frequent scans to capture treatment responses accurately in the real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Subcutaneous administration of amivantamab led to low rates of infusion-related reactions and a safety profile consistent with that historically associated with the IV administration of the drug in solid tumors. @Anna_Minchom @ICR_London #ASCO23 #oncology https://t.co/kL5zEQNGMg https://t.co/B1KH8Fj0HX
-
-
Mashup Score: 1Exclusive highlights in genitourinary cancer at ASCO 2023 - 6 month(s) ago
Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, provides important updates in genitourinary cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including findings from the PEACE-1 trial (NCT01957436), as well as updates in PARP inhibitors with radioligands in prostate cancer. Dr Barata additionally comments on trials assessing salvage chemotherapy in renal cell carcinoma (RCC) and targeting EGFR in bladder cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3The role of targeted therapies in HER2+ and HR+ breast cancer - 7 month(s) ago
Yutaka Yamamoto, MD PhD, Kumamoto University Hospital, Kumamoto, Japan, comments on the current state of targeted therapies for HER2+ and HR+ breast cancer. Although clinically applicable results for immune checkpoint inhibitors have not yet been obtained for these types of breast cancer, antibody-drug conjugates such as trastuzumab deruxtecan (T-DXd) are being rapidly developed. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone https://t.co/Dr4uputNa1 #RCC #kcsm #kidneycancer #oncology #ASCO23